Journal of Medicinal Chemistry · 2008 · 93 citations · 38 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsLead Compound DesignLigand BindingMolecular ModelingPotency OptimizationReceptor ModelingStructure-activity Relationship AnalysisBinding Mode AnalysisChemical Structure-activity RelationshipsProtein-ligand Complex ModelingStructure-based Ligand DesignTarget-ligand InteractionsVascular Endothelial Growth FactorVascular Endothelial Growth Factor ReceptorsVegfr Inhibitors
In this study we report on the design, synthesis, and biological evaluation of pyrrole-2-one 2 to be a highly potent VEGF-R2/3 inhibitor with IC 50 of 31/37 nM. The novel 3,4-diaryl-2 H-pyrrole-2-ones were designed on the basis of the modeled binding mode of the corresponding 1 H-pyrrole-2,5-dione (maleimide) VEGF-R2/3 inhibitor 1 indicating two H-bond ligand-protein interactions in the ATP pocket for the amide 2 but not for the isomer 3. Flexible synthetic routes to 3,4-diaryl-2 H-pyrrole-2-ones and structure-activity relationships for the compounds in a panel of 24 therapeutically relevant protein kinases (IC 50 values) are presented. Accordingly to the in vitro data, compounds 1 and 2 were found to possess highly potent antiangiogenic activities in the cellular HLMEC sprouting assay and also slightly induced apoptosis in HDMECs whereas 3 was determined to be significantly less active. Hence, the pyrrole-2-one moiety was dissected from the corresponding maleimide protein kinase inhibitor as a suitable key pharmacophore.
38
A small molecule–kinase interaction map for clinical kinase inhibitors
Miles A. Fabian, William Biggs, Daniel K. Treiber et al. · Nature Biotechnology · 2005 · 1.9K citations · Full text
The specificities of protein kinase inhibitors: an update
Jenny Bain, Hilary McLauchlan, Matthew Elliott et al. · Biochemical Journal · 2003 · 1.4K citations · Full text